Tokyo Tape
Sign in
← CellSeed

Annual report

7776.TEDINET S100VGWL
Period2024-01-01 → 2024-12-31
Filed2025-03-26
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 92
MetricValuePeriodScopeSource row
Revenue¥193m2024-01-01 → 2024-12-31StandaloneNet sales
Revenue¥190m2023-01-01 → 2023-12-31StandaloneNet sales
Revenue¥126m2022-01-01 → 2022-12-31dStandaloneNet sales (5-year summary)
Revenue¥162m2021-01-01 → 2021-12-31dStandaloneNet sales (5-year summary)
Revenue¥199m2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Operating income−¥846m2024-01-01 → 2024-12-31StandaloneOperating income
Operating income−¥698m2023-01-01 → 2023-12-31StandaloneOperating income
Ordinary income−¥848m2024-01-01 → 2024-12-31StandaloneOrdinary income
Ordinary income−¥710m2023-01-01 → 2023-12-31StandaloneOrdinary income
Ordinary income−¥754m2022-01-01 → 2022-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥887m2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥866m2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥745m2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥729m2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥858m2024-01-01 → 2024-12-31StandaloneIncome before income taxes
Profit before tax−¥846m2023-01-01 → 2023-12-31StandaloneIncome before income taxes
Net income (owners)−¥915m2021-01-01 → 2021-12-31dStandaloneProfit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥784m2020-01-01 → 2020-12-31dStandaloneProfit loss attributable to owners of parent (5-year summary)
Net income−¥860m2024-01-01 → 2024-12-31StandaloneProfit loss
Net income−¥847m2023-01-01 → 2023-12-31StandaloneProfit loss
Net income−¥760m2022-01-01 → 2022-12-31dStandaloneNet income loss (5-year summary)
Net income−¥913m2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Net income−¥768m2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Total assets¥2.4bnat 2024-12-31StandaloneAssets
Total assets¥2.5bnat 2023-12-31StandaloneAssets
Total assets¥1.5bnat 2022-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.4bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.4bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.8bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.8bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥270mat 2024-12-31StandaloneLiabilities
Total liabilities¥301mat 2023-12-31StandaloneLiabilities
Net assets / equity¥2.2bnat 2024-12-31StandaloneNet assets
Net assets / equity¥2.2bnat 2023-12-31StandaloneNet assets
Net assets / equity¥1.2bnat 2022-12-31dStandaloneNet assets
Net assets / equity¥1.0bnat 2021-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥1.0bnat 2021-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥1.5bnat 2020-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥1.6bnat 2020-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥2.1bnat 2024-12-31StandaloneCash and deposits
Cash and deposits¥2.2bnat 2023-12-31StandaloneCash and deposits
Cash & equivalents¥2.1bnat 2024-12-31StandaloneCash and cash equivalents
Cash & equivalents¥2.2bnat 2023-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.1bnat 2022-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥931mat 2021-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥1.5bnat 2020-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥866m2024-01-01 → 2024-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥779m2023-01-01 → 2023-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥718m2022-01-01 → 2022-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥817m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥701m2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥18m2024-01-01 → 2024-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥56m2023-01-01 → 2023-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥62m2022-01-01 → 2022-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥110m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥13m2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥855m2024-01-01 → 2024-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.8bn2023-01-01 → 2023-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥882m2022-01-01 → 2022-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥397m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.1bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-25.722024-01-01 → 2024-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-29.432023-01-01 → 2023-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.312022-01-01 → 2022-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-53.182021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-53.082021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-55.312020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-54.192020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥62.1at 2024-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥68.08at 2023-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥47.26at 2022-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥56.44at 2021-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥57.43at 2021-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥93.85at 2020-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥95.7at 2020-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio88.5%at 2024-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio86.9%at 2023-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio74.8%at 2022-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio72.0%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio72.4%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio83.2%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio83.5%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued34,666,419at 2024-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued31,459,019at 2023-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued24,422,619at 2022-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued17,759,419at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued16,008,319at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees38at 2024-12-31StandaloneNumber of employees
Employees35at 2023-12-31StandaloneNumber of employees
Employees30at 2022-12-31dStandaloneNumber of employees
Employees44at 2021-12-31dStandaloneNumber of employees
Employees40at 2020-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2024-01-01 → 2024-12-31¥16m
Reconciling Itemsreconcilingsegment assetsat 2024-12-31¥2.2bn
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-12-31−¥230m
Cell Sheet Regenerative Medicinereportable segmentemployeesat 2024-12-3122 pure
Cell Sheet Regenerative Medicinereportable segmentrevenue2024-01-01 → 2024-12-31¥1m
Cell Sheet Regenerative Medicinereportable segmentrevenue external2024-01-01 → 2024-12-31¥1m
Cell Sheet Regenerative Medicinereportable segmentsegment assetsat 2024-12-31¥70m
Cell Sheet Regenerative Medicinereportable segmentsegment profit2024-01-01 → 2024-12-31−¥596m
Laboratory Consumables And Equipmentreportable segmentcapex2024-01-01 → 2024-12-31¥2m
Laboratory Consumables And Equipmentreportable segmentemployeesat 2024-12-3111 pure
Laboratory Consumables And Equipmentreportable segmentrevenue2024-01-01 → 2024-12-31¥192m
Laboratory Consumables And Equipmentreportable segmentrevenue external2024-01-01 → 2024-12-31¥192m
Laboratory Consumables And Equipmentreportable segmentsegment assetsat 2024-12-31¥121m
Laboratory Consumables And Equipmentreportable segmentsegment profit2024-01-01 → 2024-12-31−¥21m
—segment totalcapex2024-01-01 → 2024-12-31¥2m
—segment totalrevenue2024-01-01 → 2024-12-31¥193m
—segment totalrevenue external2024-01-01 → 2024-12-31¥193m
—segment totalsegment assetsat 2024-12-31¥191m
—segment totalsegment profit2024-01-01 → 2024-12-31−¥616m
Reconciling Itemsreconcilingcapex2023-01-01 → 2023-12-31¥21m
Reconciling Itemsreconcilingsegment assetsat 2023-12-31¥2.3bn
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-12-31−¥197m
Cell Sheet Regenerative Medicinereportable segmentrevenue2023-01-01 → 2023-12-31¥8m
Cell Sheet Regenerative Medicinereportable segmentrevenue external2023-01-01 → 2023-12-31¥8m
Cell Sheet Regenerative Medicinereportable segmentsegment assetsat 2023-12-31¥65m
Cell Sheet Regenerative Medicinereportable segmentsegment profit2023-01-01 → 2023-12-31−¥469m
Laboratory Consumables And Equipmentreportable segmentcapex2023-01-01 → 2023-12-31¥770,000
Laboratory Consumables And Equipmentreportable segmentdepreciation2023-01-01 → 2023-12-31¥8m
Laboratory Consumables And Equipmentreportable segmentrevenue2023-01-01 → 2023-12-31¥182m
Laboratory Consumables And Equipmentreportable segmentrevenue external2023-01-01 → 2023-12-31¥182m
Laboratory Consumables And Equipmentreportable segmentsegment assetsat 2023-12-31¥133m
Laboratory Consumables And Equipmentreportable segmentsegment profit2023-01-01 → 2023-12-31−¥32m
—segment totalcapex2023-01-01 → 2023-12-31¥770,000
—segment totaldepreciation2023-01-01 → 2023-12-31¥8m
—segment totalrevenue2023-01-01 → 2023-12-31¥190m
—segment totalrevenue external2023-01-01 → 2023-12-31¥190m
—segment totalsegment assetsat 2023-12-31¥198m
—segment totalsegment profit2023-01-01 → 2023-12-31−¥501m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 991
ItemContextValueUnit
Operating incomePrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember-468691000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember_ReportableSegmentsMember-501129000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember_ReconcilingItemsMember-196647000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember-697776000JPY
AssetsPrior1YearInstant_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember132875000JPY
AssetsPrior1YearInstant_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember65349000JPY
AssetsPrior1YearInstant_NonConsolidatedMember_ReportableSegmentsMember198225000JPY
AssetsPrior1YearInstant_NonConsolidatedMember_ReconcilingItemsMember2267543000JPY
AssetsPrior1YearInstant_NonConsolidatedMember2465768000JPY
LiabilitiesPrior1YearInstant_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember41391000JPY
LiabilitiesPrior1YearInstant_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember58935000JPY
LiabilitiesPrior1YearInstant_NonConsolidatedMember_ReportableSegmentsMember100327000JPY
LiabilitiesPrior1YearInstant_NonConsolidatedMember_ReconcilingItemsMember200720000JPY
LiabilitiesPrior1YearInstant_NonConsolidatedMember301047000JPY
Depreciation segment informationPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember7939000JPY
Depreciation segment informationPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember－JPY
Depreciation segment informationPrior1YearDuration_NonConsolidatedMember_ReportableSegmentsMember7939000JPY
Depreciation segment informationPrior1YearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Depreciation segment informationPrior1YearDuration_NonConsolidatedMember7939000JPY
Increase in property plant and equipment and intangible assetsPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember770000JPY
Increase in property plant and equipment and intangible assetsPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember－JPY
Increase in property plant and equipment and intangible assetsPrior1YearDuration_NonConsolidatedMember_ReportableSegmentsMember770000JPY
Increase in property plant and equipment and intangible assetsPrior1YearDuration_NonConsolidatedMember_ReconcilingItemsMember20862000JPY
Increase in property plant and equipment and intangible assetsPrior1YearDuration_NonConsolidatedMember21632000JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember192059000JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember1217000JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember_ReportableSegmentsMember193277000JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember193277000JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember_ReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember－JPY
Net salesCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember192059000JPY
Net salesCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember1217000JPY
Net salesCurrentYearDuration_NonConsolidatedMember_ReportableSegmentsMember193277000JPY
Net salesCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Net salesCurrentYearDuration_NonConsolidatedMember193277000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember-20535000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember-595521000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_ReportableSegmentsMember-616057000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember-230320000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember-846378000JPY
AssetsCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember120594000JPY
AssetsCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember69945000JPY
AssetsCurrentYearInstant_NonConsolidatedMember_ReportableSegmentsMember190540000JPY
AssetsCurrentYearInstant_NonConsolidatedMember_ReconcilingItemsMember2242544000JPY
AssetsCurrentYearInstant_NonConsolidatedMember2433084000JPY
LiabilitiesCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember44025000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2023-12-31pass
balance sheet identitynon_consolidated 2024-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-12-31pass
statement vs summary · operating cash flownon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · operating cash flownon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · total assetsnon_consolidated 2023-12-31pass
statement vs summary · total assetsnon_consolidated 2024-12-31pass